| Mechanisms for estrogen receptor expression in human cancer |
26 |
| The role of neoantigen in immune checkpoint blockade therapy |
24 |
| Emerging therapies in advanced hepatocellular carcinoma |
16 |
| Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine |
15 |
| Advances and perspectives of PARP inhibitors |
13 |
| Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer |
13 |
| Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma |
12 |
| Recent advances on blinatumomab for acute lymphoblastic leukemia |
11 |
| An integrated view of the role of miR-130b/301b miRNA cluster in prostate cancer |
9 |
| Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose |
9 |
| Targeted and novel therapy in advanced gastric cancer |
9 |
| Immunotherapy in extensive small cell lung cancer |
9 |
| Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States |
6 |
| Daratumumab binds to mobilized CD34+cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth |
6 |
| Mantle cell lymphoma and its management: where are we now? |
6 |
| Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma |
6 |
| WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia |
6 |
| An expanded biomarker panel for the detection of prostate cancer from urine DNA |
6 |
| Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia |
5 |
| The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis |
5 |
| Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia |
5 |
| Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma |
5 |
| Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature |
5 |
| Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report |
5 |
| Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy |
4 |
| Novel GTF2I-PDGFRB and IKZF1-TYW1 fusions in pediatric leukemia with normal karyotype |
4 |
| Frontline therapies for untreated chronic lymphoid leukemia |
4 |
| NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children |
4 |
| Gut microbiome and CAR-T therapy |
4 |
| Bone marrow transplant-associated thrombotic microangiopathy without peripheral blood schistocytes: a case report and review of the literature |
3 |
| Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation |
3 |
| Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin |
3 |
| PAN3-PSMA2 fusion resulting from a novel t(7;13)(p14;q12) chromosome translocation in a myelodysplastic syndrome that evolved into acute myeloid leukemia |
3 |
| Early detection of transformation to BPDCN in a patient with MDS |
3 |
| Role of some members of chemokine/cytokine network in the pathogenesis of thalassemia and sickle cell hemoglobinopathies: a mini review |
3 |
| Bullous hemorrhagic dermatosis is an under-recognized side effect of full dose low-molecular weight heparin: a case report and review of the literature |
3 |
| Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration |
2 |
| The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994-2016 |
2 |
| Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib |
2 |
| Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data |
2 |
| Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide |
2 |
| A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma |
2 |
| Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma |
2 |
| Methylome of human senescent hematopoietic progenitors |
1 |
| A novel RNA variant of human concentrative nucleoside transporter 1 (hCNT1) that is a potential cancer biomarker |
1 |
| Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant |
1 |
| Understanding metabolic changes in aging bone marrow |
1 |
| Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation |
1 |
| The association of HLA-C alleles with multiple myeloma in Chinese patients |
1 |
| A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma |
1 |
